Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of Exenatide, Insulin or Pioglitazone on Glycaemic Control and β-cell Function in Drug-naive Type 2 Diabetic Patients: A Multicentre Randomized Parallel-group Trial

Next Previous
Trial Profile

Comparison of Exenatide, Insulin or Pioglitazone on Glycaemic Control and β-cell Function in Drug-naive Type 2 Diabetic Patients: A Multicentre Randomized Parallel-group Trial

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary) ; Insulin neutral protamine lispro/insulin lispro (Primary) ; Pioglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms CONFIDENCE

    • Most Recent Events

    • 01 Apr 2022 Results (n=100) assessing the association between variant rs163184 in the type 2 diabetes mellitus susceptibility gene KCNQ1 and exenatide glycemic response in the Chinese population, published in the Pharmacogenomics.
    • 01 Aug 2015 Primary endpoint has been met. (Comparison Between Treatment Group (exenatide versus pioglitazone) of the Changes From Baseline in HbA1c at 48 Weeks), as per an article published in the Clinical Therapeutics.
    • 01 Aug 2015 Primary endpoint has not been met. (Comparison Between Treatment Group (exenatide versus insulin) of the Changes From Baseline in HbA1c at 48 Weeks), as per an article published in the Clinical Therapeutics.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top